214 related articles for article (PubMed ID: 19526202)
1. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Al-Tweigeri TA; Ajarim DS; Alsayed AA; Rahal MM; Alshabanah MO; Tulbah AM; Al-Malik OA; Fatani DM; El-Husseiny GA; Elkum NB; Ezzat AA
Med Oncol; 2010 Sep; 27(3):571-7. PubMed ID: 19526202
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Ezzat AA; Ibrahim EM; Ajarim DS; Rahal MM; Raja MA; Tulbah AM; Al-Malik OA; Al-Shabanah M; Sorbris R
Br J Cancer; 2004 Mar; 90(5):968-74. PubMed ID: 14997191
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers.
Lee YJ; Doliny P; Gomez-Fernandez C; Powell J; Reis I; Hurley J
Clin Breast Cancer; 2004 Dec; 5(5):371-6. PubMed ID: 15585076
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
9. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Hurley J; Doliny P; Reis I; Silva O; Gomez-Fernandez C; Velez P; Pauletti G; Powell JE; Pegram MD; Slamon DJ
J Clin Oncol; 2006 Apr; 24(12):1831-8. PubMed ID: 16549824
[TBL] [Abstract][Full Text] [Related]
12. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.
Montero AJ; Diaz-Montero CM; Deutsch YE; Hurley J; Koniaris LG; Rumboldt T; Yasir S; Jorda M; Garret-Mayer E; Avisar E; Slingerland J; Silva O; Welsh C; Schuhwerk K; Seo P; Pegram MD; Glück S
Breast Cancer Res Treat; 2012 Feb; 132(1):215-23. PubMed ID: 22138748
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jeong JH; Jung SY; Park IH; Lee KS; Kang HS; Kim SW; Kwon Y; Kim EA; Ko KL; Nam BH; Lee S; Ro J
Invest New Drugs; 2012 Feb; 30(1):408-16. PubMed ID: 20922557
[TBL] [Abstract][Full Text] [Related]
15. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.
Ezzat AA; Ibrahim EM; Ajarim DS; Rahal MM; Raja MA; Stuart RK; Tulbah AM; Kandil A; Al-Malik OA; Bazarbashi SM
Breast Cancer Res Treat; 2000 Aug; 62(3):237-44. PubMed ID: 11072788
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
Malhotra V; Dorr VJ; Lyss AP; Anderson CM; Westgate S; Reynolds M; Barrett B; Perry MC
Clin Breast Cancer; 2004 Dec; 5(5):377-84. PubMed ID: 15585077
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Lu YS; Chen DR; Tseng LM; Yeh DC; Chen ST; Hsieh CM; Wang HC; Yeh HT; Kuo SH; Huang CS
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1257-63. PubMed ID: 20700740
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
